WO2023094699A1 - Inhibiteurs de la phosphorylation anormale et de l'agrégation de la protéine tau - Google Patents
Inhibiteurs de la phosphorylation anormale et de l'agrégation de la protéine tau Download PDFInfo
- Publication number
- WO2023094699A1 WO2023094699A1 PCT/EP2022/083709 EP2022083709W WO2023094699A1 WO 2023094699 A1 WO2023094699 A1 WO 2023094699A1 EP 2022083709 W EP2022083709 W EP 2022083709W WO 2023094699 A1 WO2023094699 A1 WO 2023094699A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tau
- compound
- group
- nmr
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to lipid anionic oligosaccharides and their uses in medicine, more particularly in the treatment of pathologies associated with abnormal hyperphosphorylation of the Tau protein, such as Alzheimer's disease.
- AD Alzheimer's disease
- WHO World Health Organization
- AD is characterized by a progressive loss of cognitive abilities linked to severe degeneration of neurons. Histopathologically, AD is characterized by two types of cerebral lesions: on the one hand, senile (or amyloid) plaques which are extracellular aggregates of beta-amyloid (A ⁇ ) peptides and on the other hand, deposits/ neurofibrillary degenerations (DNFs) corresponding to the intracellular accumulation of abnormally phosphorylated Tau protein (MAPT, microtubule-associated protein Tau) (P-Tau).
- a ⁇ beta-amyloid
- DNFs neurofibrillary degenerations
- amyloid plaques and DNFs made of P-Tau in the functional alterations of neuronal cells being well accepted, most of the treatments developed have notably targeted the progressive accumulation of beta-amyloid protein and more recently of Tau.
- treatment failures of strategies targeting different episodes of the amyloid J3 (AJ3) cascade have indicated that AJ3 accumulation is not the central disease process in the disease, but may be phosphorylation abnormal and Tau aggregation that should be targeted in order to combat this disease.
- the Tau protein is part of the family of microtubule-associated proteins (MAP proteins). In humans, one of the main roles of the Tau protein is to stabilize the cytoskeleton of neurons via its interaction with tubulin allowing axonal stability.
- AD the abnormal phosphorylation of Tau induces the detachment of the protein from the cytoskeleton, the thus soluble Tau protein aggregates to finally form the DNFs characteristic of AD.
- a direct correlation has been shown between the clinical course of the pathology and the accumulation of abnormally phosphorylated and aggregated Tau protein in the form of neurofibrillary tangles (NFTs) in the brain.
- NFTs neurofibrillary tangles
- kinases are able to phosphorylate Tau (cdK5, NCLK, GSK-3 ⁇ and MARK), but this is done in a non-specific way since several other proteins are also their substrates. Thus, inhibiting one of the kinases will not prevent the action of the others.
- kinase inhibitors and also on phosphatases (also non-specific), considered as therapeutic targets, no positive result making it possible to stop or slow down the disease by inhibiting the activity of these enzymes individually has not been obtained to date, either by kinase inhibitors, or else by phosphatase activators, or by agents for dissociating DNFs.
- the treatments in development targeting the Tau protein are mainly based on immunotherapy at the extracellular level.
- the antibodies used are directed against fragments of Tau with the aim of reducing the extracellular forms of the more or less aggregated Tau protein.
- these extracellular forms are generated at the intracellular level by the phosphorylation of the Tau protein, after secretion at the extracellular level these aggregated forms of Tau seem to serve for the propagation of the pathology in the brain tissue.
- the present invention relates to compounds of the following formula (I): in which :
- R 1 is a hydrocarbon chain, linear or branched, saturated or unsaturated, comprising 15, 16, 17 or 18 carbon atoms, optionally substituted in the terminal position by a group chosen from -OH, -OR, -NH 2 , -NHR, -NRR', -COOH, -COOR, -CONHR, -CONRR', -SR with R and R' denoting, independently of one another, an alkyl group comprising from one to six carbon atoms;
- R4 is a group of formula (IIa) or (IIb): in which :
- R 9 and R 10 are, independently of each other, a hydrogen atom or a sulphonate group in ionized form
- R12 is an alkyl group comprising from one to six carbon atoms
- R 11 is a -CH 2 -OR 5 or -CONHR 13 group in which:
- R 5 is a hydrogen atom or a sulphonate group in ionized form
- R13 is an alkyl group comprising from one to six carbon atoms
- R 2 , R 3 , R 5 , R 7 and R 8 are, independently of one another, a hydrogen atom or a sulphonate group in ionized form; And in which at least one of the groups R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 , preferably at least two of the groups R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are a sulphonate group in ionized form, for their use in medicine, in particular in the treatment of tauopathies.
- the present invention also relates to pharmaceutical compositions comprising at least one compound of formula (I) as described herein and one or more pharmaceutically acceptable excipients and their use in the treatment of tauopathies.
- Figure 1 Illustration of the role of heparan sulphates (HS).
- Figure 2 Western-blot showing that Tau phosphorylation at sites characteristic of Alzeimer's disease mediated by GSK3[3 is dependent on the presence of heparin in the reaction mixture (Sepulveda-Diaz JE et al., Brain 2015 May;138(Pt 5):1339-54).
- FIG. 3 Western-blot showing that the abnormal phosphorylation of Tau (P-Tau), revealed by the antibodies characteristic of Alzheimer's disease (AT270 and Ser199/202), is inhibited by the presence of di-sulphated C16 maltobionamides ( Mal16diS) after 3 hours of in vitro reaction.
- P-Tau abnormal phosphorylation of Tau
- AT270 and Ser199/202 antibodies characteristic of Alzheimer's disease
- Mal16diS di-sulphated C16 maltobionamides
- FIG. 4 Western-blot showing that the abnormal phosphorylation of Tau (p-Tau), revealed by the antibodies characteristic of Alzheimer's disease (AT270, pSerl 99/202) is inhibited by the presence of di-sulfated C18 maltobionamides ( Mal18diS) after 3 hours of reaction.
- p-Tau abnormal phosphorylation of Tau
- AT270, pSerl 99/202 antibodies characteristic of Alzheimer's disease
- Mal18diS di-sulfated C18 maltobionamides
- Figure 5 Western-blot comparing the p-Tau induction capacity (revealed by the AT270 antibody) of disulfated maltobionamide-derived compounds as a function of the length of the hydrocarbon chain (R 1 ) (Mal14diS to Mal20diS corresponding to chains of 14 to 20 carbons) and heparin (“Hep”) after 3 hours of reaction.
- FIG. 6 Western-blot evaluating the abnormal phosphorylation of Tau (p-Tau), revealed by the antibodies characteristic of Alzheimer's disease (AT270 and Ser199/202) for the various derivatives according to their disaccharide (mono or disulfated) and the hydrocarbon chain length (14 to 20 carbons) after 3 hours of reaction.
- p-Tau abnormal phosphorylation of Tau
- Figure 7 Western-blot comparing the ability to protect the Tau protein from its abnormal heparin-induced phosphorylation, revealed by the AT270 antibody, of the disulfated maltobionamides (Mal16diS, Mal18diS) compared to the 16-oxidized forms (Mal16diOx) and 18 carbons (Mal18diOx).
- Figure 8 Western-blot comparing the effect of sulfation (monoS and triS) of the disaccharide on the ability of 16- or 18-carbon maltobionamides to effectively protect Tau from its abnormal phosphorylation induced by heparin, revealed by the AT270 antibody with 2 batches of compounds (Mal16monoS, Mal16triS for Mal16 and Mal18monoS, Mal18triS for Mal18).
- Figure 9 Western-blot comparing persulfated 16-carbon maltobionamide molecules (Mal16perS) to their effective disulfated counterparts (Mal16diS, Mal18diS) in their ability to effectively protect Tau from its abnormal heparin-induced phosphorylation, revealed by the antibody AT270.
- Figure 10 Monitoring of the aggregation of the Tau protein by integration of Thioflavin-T, a fluorescent compound which integrates into the aggregates, in the presence of heparin (mass ratio Tau: Hep of 2:1 or 4:1) or the 16-carbon disulfated maltobionamide compound (Mal16diS) (mass ratio Tau:oligo, 4:1).
- n represents the number of repetitions.
- Figure 11 Cytotoxicity of 16-carbon disulfated maltobionamides (Mal16diS) at concentrations of 0.1, 1, 10, or 100 pg/ml.
- Figure 12 Cytotoxicity of 18-carbon disulfated maltobionamide (Mal18diS) at concentrations of 0.1, 1, 1, 10 or 100 pg/ml.
- Figure 13 Protection of Tau phosphorylation in cellulo by 16-carbon disulfated maltobionamide compounds (Mal16diS) at concentrations of 1, 10 or 100 pg/ml. t-test: * p ⁇ 0.05, *** p ⁇ 0.001; number of replicates ⁇ 5.
- Figure 14 Protection of Tau phosphorylation in cellulo by 18-carbon disulfated maltobionamide compounds (Mal18diS) at concentrations of 1, 10 or 100 pg/ml. t-test: * p ⁇ 0.05, *** p ⁇ 0.001; number of replicates ⁇ 5.
- Figure 15 Effect of Cell16diS on p-tau in cellulo in the SHSY5Y model with induction of tauopathy. t-test not significant, number of replicates ⁇ 3.
- Figure 16 Effect of Lac16diS on p-tau in cellulo in the SHSY5Y model with induction of tauopathy. t-test: * p ⁇ 0.05; number of replicates ⁇ 3
- lipid anionic oligosaccharides as described below are capable of protecting the Tau protein from its abnormal hyperphosphorylation, of not inducing the abnormal hyperphosphorylation of Tau themselves and of reduce heparin-induced tau protein aggregation, the prototype of the hypersulfated heparan sulfates present in AIzeimer's disease (Sepulveda-Diaz JE et al., Brain. 2015 May;138(Pt 5): 1339-54) .
- the lipid anionic oligosaccharides of the present invention therefore prove to be useful in the treatment of pathologies associated with abnormal hyperphosphorylation of the Tau protein, and more particularly in the treatment of Alzheimer's disease.
- the compounds may prove capable of halting or slowing the progression of the pathology.
- Heparan sulphates are copolymers of uronic acid (D-glucuronic or L-iduronic) and D-glucosamine which can be N-acetylated and contain sulphated sites.
- the Gly-CRRET laboratory has shown in particular that the change in conformation of Tau allowing its abnormal hyperphosphorylation and its aggregation in neuronal cells results from the interaction of the protein with chains of heparan sulphate (HS) internalized in the neurons of the subjects. sick.
- HS heparan sulphate
- HS are receptors for Tau aggregates ('proteopathic seeds') on the surface of cells and that they participate centrally in the transfer of fibrils from Tau from a diseased cell to a healthy cell, processes known as 'spreading' (Holmes BB et al., Proc Natl Acad Sci US A. 2013 Aug 13;110(33); Tau spreading is currently thought to be responsible spread of the disease between cells and between different regions of the brain.
- R 1 is a hydrocarbon chain, linear or branched, saturated or unsaturated, comprising 15, 16, 17 or 18 carbon atoms, optionally substituted in the terminal position by a group chosen from -OH, -OR, -NH 2 , -NHR, -NRR', -COOH, -COOR, -CONHR, -CONRR', -SR with R and R' denoting, independently of one another, an alkyl group comprising from one to six carbon atoms;
- R4 is a group of formula (IIa) or (IIb): in which :
- R 9 and RTM are, independently of each other, a hydrogen atom or a sulphonate group in ionized form
- R12 is an alkyl group comprising from one to six carbon atoms
- R11 is a -CH 2 -OR 5 or -CONHR 13 group in which:
- R 5 is a hydrogen atom or a sulphonate group in ionized form
- R13 is an alkyl group comprising from one to six carbon atoms;
- R 2 , R 3 , R 6 , R 7 and R 8 are, independently of each other, a hydrogen atom or a sulphonate group in ionized form; and in which at least one of the groups R 2 , R 3 , R 5 , R 7 , R 8 , R 9 and R 10 , preferably at least two of the groups R 2 , R 3 , R 5 , R 7 , R 8 , R 9 and R 10 are a sulphonate group in ionized form.
- the compounds of the present invention or useful in the context of the present invention are compounds of formula (I) below: in which :
- R 1 is a hydrocarbon chain, linear or branched, saturated or unsaturated, comprising 15, 16, 17 or 18 carbon atoms, optionally substituted in the terminal position by a group chosen from -OH, -OR, -NH 2 , -NHR, -NRR', -COOH, -COOR, -CONHR, -CONRR', -SR with R and R′ denoting independently of one another an alkyl group comprising from one to six carbon atoms;
- R 2 is a hydrogen atom or a sulphonate group in ionized form
- R 3 is a hydrogen atom or a sulphonate group in ionized form
- R4 is a group of formula (IIa): in which :
- R 9 and RTM are, independently of each other, a hydrogen atom or a sulphonate group in ionized form
- R 5 , R 7 and R 8 are, independently of each other, a hydrogen atom or a sulphonate group in ionized form;
- R 6 is a hydrogen atom or a sulphonate group in ionized form; and in which at least one of the groups R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 , preferably at least two of the groups R 2 , R 3 , R 6 , R 7 , R 8 , R 9 and R 10 , are a sulphonate group in ionized form.
- sulfonate group in ionized form denotes the —SO 3 — group.
- the compounds of formula (I) are preferably in the form of salts, in particular in the form of sodium salts.
- the sulphonate groups in ionized form are preferably sodium sulphonate groups (-SO 3 Na).
- the compounds of formula (I) have two, three, four, five, six, seven or eight sulphonate groups in ionized form.
- two, three, four, five, six, seven or all of the R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 groups are sulfonate groups in ionized form.
- compounds comprising two or three ionized sulphonate groups can be preferred.
- the compounds of the present invention or useful within the scope of the present invention have the following formula (Ia): in which R 1 to R 8 are as described above and in which at least one of the groups R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 , preferably at least two of the groups R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are a sulphonate group in ionized form.
- the compounds of the present invention or useful within the scope of the present invention have the following formula (Ib): in which R 1 to R 3 and R 5 to R 10 are as described above or below and in which at least one of the groups R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 , preferably at least two of the groups R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 , are a sulphonate group in ionized form.
- R 1 is preferably a saturated linear hydrocarbon chain comprising 15, 16, 17 or 18 carbon atoms, preferably 16 and 18 carbon atoms.
- R 2 , R 3 and R 10 are preferably a hydrogen atom.
- R 5 is preferably a sulphonate group in ionized form and R 6 , R 7 and R 8 are hydrogen atoms.
- R 9 is preferably a sulphonate group in ionized form.
- the compounds of the present invention or useful within the scope of the present invention have the following formula (Ib): in which: R 1 is a saturated linear hydrocarbon chain comprising 15, 16, 17 or 18 carbon atoms, preferably 16 or 18 carbon atoms; R 2 , R 3 , R 6 , R 7 , R 8 and R 10 are hydrogen atoms, or only one of the R 2 , R 3 , R 6 , R 7 , R 8 and R 10 groups is a sulphonate group in ionized form and the other groups are hydrogen atoms; And
- R 5 and R 9 are sulphonate groups in ionized form.
- the compounds of the present invention or useful within the scope of the present invention have the following formula (Ib):
- R 1 is a saturated linear hydrocarbon chain comprising 15, 16, 17 or 18 carbon atoms, preferably 16 or 18 carbon atoms;
- R 2 , R 3 , R 6 , R 7 , R 8 and R 10 are hydrogen atoms;
- R 5 and R 9 are sulphonate groups in ionized form.
- the compounds of the present invention or useful within the scope of the present invention have the following structure: wherein R 1 to R 3 and R 5 to R 10 are as described above.
- the compounds of the present invention or useful within the scope of the present invention have the following structure (Id): (Id) in which R 1 , R 2 , R 3 and R 6 to R 8 and R 10 are as described above.
- the compounds of the present invention or useful within the scope of the present invention have the following structure: wherein R 1 to R 3 and R 5 to R 10 are as described above.
- the compounds of the present invention or useful within the scope of the present invention have the following structure (If): wherein R 1 , R 2 , R 3 and R 6 to R 8 and R 10 are as described above.
- the compounds of the present invention or useful within the scope of the present invention have the following structure (Ig): wherein R 1 to R 3 and R 5 to R 10 are as described above.
- the compounds of the present invention or useful within the scope of the present invention have the following structure (Ih): wherein R 1 , R 2 , R 3 and R 6 to R 8 and R 10 are as described above.
- the compounds of the present invention are compounds of formula (I) provided that the compound is not sodium hexadecyl D-lactobionamide (2,5) sulfate, i.e. sodium hexadecyl D-lactobionamide disulfate, sodium hexadecyl D-lactobionamide trisulfate and mixtures thereof.
- Non-limiting examples of compounds of formula (I) include the compounds of formula (I) shown in Table 1 in the “Examples” section.
- the compounds of formula (I) can be prepared in 3 steps from a disaccharide, such as maltose, cellobiose or lactose.
- a disaccharide such as maltose, cellobiose or lactose. The process includes the following steps:
- step 1 oxidation of the anomeric position of the disaccharide
- step 2 synthesis of the methyl ester and aminolysis to graft the hydrocarbon chain (R-i) in solvent-free condition by mechanosynthesis;
- step 3 selective sulfation of primary hydroxyl groups or persulfation.
- the disaccharide is maltose. It is understood that the maltose can be replaced by any suitable disaccharide.
- Diagram 1 synthetic route of the compounds of formula (I) from maltose
- Step 1
- the oxidation of the anomeric position of the disaccharide can be carried out according to well-known methods, such as for example by method A described in ACS Sustainable Chemistry & Engineering 2016, 4(4), 2432-2438.
- sodium maltobionate can be prepared by photocatalysis (Omri M. et al., ACS Catalysis 2018) with the same conversion rate: >99%, selectivity: >95% (estimated by NMR).
- Step 2 one-pot synthesis of A/-alkyl D-maltobionamide derivative
- the potassium glycobionate is ground in the presence of a supported acid catalyst (H 2 SO 4 /SiO2) and methanol (in an amount just necessary to methylate the carboxylic acid formed) in a ball mill, then in a second step with the alkylamine added after complete conversion of the glycobionate to ester.
- Quantitative conversion rates for stage 2, typically greater than 85%, can be obtained for all of the two stages.
- Stage 3 The sulfation stage is carried out according to a protocol from the literature in a pyridine medium in the presence of a sulphating agent, SO 3 -pyridine (Tetrahedron. 2010 Apr 17; 66(16): 2907-2918).
- a compound of formula (I) designates a compound of formula (I) as described above, including the compounds described in the “Examples” section.
- the expression “a compound of formula (I)” denotes a single compound of formula (I) or a mixture of two or more compounds of formula (I).
- the compounds of formula (I) effectively protect the Tau protein from its abnormal hyperphosphorylation induced by heparin, weakly induce the phosphorylation of the Tau protein and reduce the aggregation of the Tau protein induced by heparin.
- the compounds of formula (I) therefore prove to be useful in medicine, especially in the treatment of pathologies linked to abnormal hyperphosphorylation or phosphorylation of the Tau protein (Tauopathy), and especially in the treatment of Alzheimer's disease .
- the compounds of formula (I) would make it possible to act by inhibiting the abnormal phosphorylation of Tau, not by inhibiting the kinases but by protecting Tau from their attack, and this upstream of the process of aggregation and propagation of the aggregates.
- the present invention relates to a compound of formula (I) for its use in medicine or, formulated differently, as a medicament.
- tauopathies include Alzheimer's disease, frontotemporal dementia with parkinsonism on chromosome 17 (DFTP17), Pick's disease, corticobasal degeneration, progressive supranuclear palsy (PSP).
- tauopathies include Alzheimer's disease, frontotemporal dementia with parkinsonism on chromosome 17 (DFTP17), Pick's disease, corticobasal degeneration, progressive supranuclear palsy (PSP).
- the present invention relates to a compound of formula (I) for its use in the treatment of Alzheimer's disease, frontotemporal dementia with parkinsonism in chromosome 17 (DFTP17), disease, corticobasal degeneration or progressive supranuclear palsy.
- the present invention relates to a compound of formula (I) for its use in the treatment of Alzheimer's disease.
- the present invention also relates to the use of a compound of formula (I) for the preparation of a medicament useful in the treatment of pathologies linked to abnormal hyperphosphorylation or phosphorylation of the Tau protein (Tauopathy), and most particularly in Alzheimer's treatment.
- the present invention also relates to a pharmaceutical composition, in particular a medicament, comprising a compound of formula (I) and one or more excipients, in particular one or more pharmaceutically acceptable excipients and their uses in
- pharmaceutically acceptable means that which is known to be non-toxic and which can be used in the field of medicine.
- Pharmaceutically acceptable excipients are well known in the medical literature.
- excipients are chosen according to the desired pharmaceutical form and mode of administration.
- compositions according to the invention can be administered parenterally, such as intravenously or intradermally, or topically, orally or nasally.
- Parenteral forms include aqueous suspensions, solutions
- isotonic saline or sterile and injectable solutions which may contain pharmacologically compatible dispersing agents and/or wetting agents.
- Orally administrable forms include tablets which may be dispersible, orodispersible, effervescent or soluble, soft or hard capsules, powders, granules, oral solutions and suspensions.
- Nasal forms include aerosols.
- the manageable forms include tablets which may be dispersible, orodispersible, effervescent or soluble, soft or hard capsules, powders, granules, oral solutions and suspensions.
- the compounds or compositions of the invention are administered orally or parenterally (in particular intravenously).
- the present invention also relates to a method for treating the pathologies indicated above which comprises the administration, to an individual in need thereof, of a dose
- the effective dose of a compound of formula (I) varies according to many parameters such as, for example, the chosen route of administration, weight, age, sex, state of progress of the pathology to be treated and the sensitivity of the individual to be treated.
- parameters such as, for example, the chosen route of administration, weight, age, sex, state of progress of the pathology to be treated and the sensitivity of the individual to be treated.
- the following examples are given for illustrative purposes, but should in no way be considered as limiting the present invention.
- the reagents used come from the companies Merck, Acros or Alfa Aesar and are used without purification.
- the solvents are purchased either in anhydrous form or are distilled under an inert atmosphere and packaged on a 3 or 4 Angstrom molecular sieve. b) Ball mill
- Thin Layer Chromatography TLC. Thin layer chromatographies are carried out on silica plates with ALUGRAM® Xtra SIL G/UV254 aluminum support for the normal phase or ALUGRAM® RP-18Z UV254 for the reversed phase.
- the techniques used to reveal the products after elution are: H 2 SO 4 /EtOH at 4% or cerium (IV) molybdate: (NH 4 )4Ce(SO 4 ).2H 2 O, (NH 4 ) 6 Mo 7 O 24.4H 2 O, H 2 SO 4 , H 2 O (2.1 g/5.3 g/12 mL/188 mL) then heating. Automated flash chromatography.
- the concentration c is expressed in grams per 100 mL of solvent.
- the low-resolution mass spectrometry analyzes were carried out on a simple quadrupole device (Micromass-Waters ZQ) equipped with an electrospray ionization source (Z-spray).
- the device allows analysis in positive or negative ionization mode.
- the capillary voltage is 3.5 kV and the variable cone voltage is 20 to 120 V.
- the source and desolvation temperatures are 80 and 150°C respectively.
- the desolvation and nebulization gas is nitrogen.
- the high-resolution mass spectrometry (HRMS) analyzes were carried out on a time-of-flight quadrupole hybrid mass spectrometer (Micromass-Waters Q-TOF Ultima Global), equipped with an electrospray ionization source.
- the source and desolvation temperatures are 80 and 120°C, respectively.
- the gas used, for nebulization and desolvation is nitrogen with a respective flow rate of 20 and 500 L/h.
- the capillary voltage is 3.5 kV and the cone voltage varies from 100 to 250 V.
- a calibration is carried out with orthophosphoric acid. The precision of the exact mass measurement of the Q-TOF being less than 5 ppm, access to the elementary composition of the molecules is possible.
- NMR spectrometry The 1 H and 13 C NMR spectra were carried out on a Bruker Advance 400 or 600 MHz spectrometer. The 1 H NMR spectra are recorded at 400 MHz or 600 MHz and the 13 C NMR spectra at 101 MHz or 150 MHz. All the experiments are carried out at a temperature close to 25°C, in a deuterated solvent which also serves as a reference. THE chemical shifts are given in ppm, coupling constants in Hertz. NMR spectra are processed using MestReNova.
- a 5% aqueous solution of disaccharide (250 mg in 5 mL of MilliQ water) is placed in a 10 mL CEM microwave tube, then 2 equivalents of K 2 CO 3 and 2.5 mg of Au/Al 2 O 3 catalyst prepared according to the protocol described in the ACS Sustainable Chem. Eng., 2016, 4, 2432-2438, are added, and the mixture is subjected to ultrasound in order to homogenize. Then 1.8 equivalents of H 2 O 2 at 30% in water are added then the mixture is placed in a CEM Discover microwave and irradiated at 60° C., using the Dynamic program for a period of 20 min. The catalyst is then filtered through 0.25 ⁇ m PVDF or removed by centrifugation.
- the filtrate is then freeze-dried and the reaction crude analyzed by 1 H NMR in order to check the total conversion of the aldose to aldonate.
- the reaction can be carried out on 1 g of disaccharide in a 35 mL tube with a reaction time of 50 min to 70 min depending on the disaccharide.
- Protocol for the synthesis of A/-alkyl-D-glycobionamide via methyl D-glycobionate One gram of potassium glycobionate reaction crude and 1.1 eq ( ⁇ 1g) of sulfuric acid supported on silica (H2S ⁇ 4/Commercial SiO2 22%) are placed in a 20 mL zirconia bowl fitted with 80 5 mm zirconia balls (ZrO 2 ). One milliliter of methanol is added and the mixture is ground at 500 rpm for 8 cycles of 5 min in P7PL. The reaction is then monitored by thin layer chromatography (TLC) in the normal phase (eluent: ethyl acetate/methanol/water 7/2/1).
- TLC thin layer chromatography
- the amine (1.5 eq.) is then added to the reaction medium in the bowl, followed by 2 mL of methanol. Grinding is continued for 12 ⁇ 5 min at 500 rpm. The reaction is again checked by TLC with the same eluent. Once the reaction is complete, the reaction medium is left to dry at ambient temperature. This reground powder is then mixed with unground silica and subjected to purification by flash chromatography using the same eluent as for monitoring the reaction. The fraction containing the glycobionamide is concentrated using a rotary evaporator before being freeze-dried.
- Disulfated compounds (disulfated A/-alkyl-glyconamides) or trisulfated N-alkyl maltotrionamides are the majority products obtained in the reaction medium, with minor formation of compounds that are not totally sulfated on the primary positions or that contain an additional sulfate.
- the reaction crude is then purified by flash reverse phase chromatography with a C18 80g Reveleris column.
- the mobile phase is a water/methanol mixture with a flow rate of 40 mL/min and a gradient starting with 40% methanol to go up to 80% methanol in 10 min.
- the fractions of purified monosulphated, disulphated (very predominant) A/-alkyl glycobionamides or trisulphated A/-alkyl maltotrionamides are then evaporated to remove the methanol and then freeze-dried.
- the monosulfated fraction of Mall 6 is obtained from crude Mal16diS purified on a flash column. It is a mixture of A/-hexadecyl maltobionamide sulphated in position 6 and its homolog sulphated in position 6'
- the trisulfated fraction of Mal16 is obtained from crude Mal16diS purified on a flash column. It is a mixture of several A/-hexadecyl maltobionamide compounds disulfated in position 6 and 6' comprising a 3 rd sulfate on one of the secondary positions.
- the monosulfated fraction of Mali 8 is obtained from crude Mal18diS purified on a flash column. It is a mixture of A/-octadecyl maltobionamide sulphated in position 6 and its homolog sulphated in position 6'
- the trisulfated fraction of Mal18 is obtained from crude Mal18diS purified on a flash column. It is a mixture of several A/-octadecyl maltobionamide compounds disulfated in position 6 and 6' comprising a 3 rd sulfate on one of the secondary positions.
- the compound /V-hexadecyl-D-maltobionamide (Mal16) 200 mg, 0.34 mmol
- 20 equivalents of SO 3 /97% active pyridine complex are introduced into a 20 mL zirconia bowl containing 80 zirconia beads with a diameter of 5 mm and then into the Fritsch P7PL planetary mill.
- the mixture is ground at 400 rpm for 48 cycles of 5 min.
- 30 equivalents of NaHCO 3 (578 mg, 6.88 mmol) are introduced into the bowl and the mixture is ground again for 6 cycles of 5 minutes.
- the reaction crude is then dissolved in milliQ water and dialyzed using a 1000 kD cut-off membrane (3x 500 mL).
- Mal16perS is composed of a mixture of A/-hexadecyl-D-maltobionamides tri, tetra, penta, hexa, hepta and octa sulfates (524 mg).
- Diagram 2 Synthesis pathway of oxidized glycobionamides
- oxidized glycobionamides involves 3 steps, the first 2 of which are identical to the synthesis of sulfated derivatives: oxidation of the anomeric position and one-pot esterification-aminolysis to graft the lipid chain via an amide bond.
- Step 3 Oxidation of the primary hydroxyls of the disaccharide by the TEMPO/BAIB, NaHCO 3 system in a CH 3 CN/H 2 O mixture (48 h) (Lu, H. et al., Molecules 2016, 21(10), 1301/ 1-1301/15). NMR and HRMS analysis show that a loss of -C6 carbon (by decarboxylation) has occurred, similar to what has been described in the literature, with a pyruvate motif (Coggins, AJ et al., Nature Chemistry 2017, 9(4), 310-317; Lee Y et al., Chem Commun 2014, 50).
- step 5 A/-hexadecyl-D-glucuronyl-(a-1,4)-D-xyluronamide (Mal16diOx)
- the /V-hexadecyl-maltobionamide derivative (0.60 mmol, 350 mg) is dissolved in a mixture of acetonitrile (4 ml) and H 2 O mQ (4 ml). The mixture is stirred at 0° C.
- the A/-hexadecyl-maltobionamide derivative (0.82 mmol, 500 mg) is dissolved in a mixture of acetonitrile (5 ml) and H 2 O mQ (5 ml). The mixture is stirred at 0° C. and TEMPO (1.64 mmol, 256 mg) is added, followed by BAIB (8.20 mmol, 2.64 g) and NaHCO 3 (4.10 mmol, 344 mg). Then, the mixture is stirred at room temperature for 48 hours. Ethanol (5 ml) is added and the reaction medium is diluted with AcOEt (200 ml) and H 2 O mQ (200 ml).
- the aqueous phase is isolated and extracted with AcOEt (2 x 200 ml), then freeze-dried.
- the reaction crude is then purified by reverse phase chromatography.
- the elution gradient is H 2 O/MeCN: 100/0 to 0/100 in 20 min. After evaporation and freeze-drying, the Mal18diOx compound is obtained in the form of a white powder, with a yield of 17% (90 mg).
- the A/-hexadecyl-D-glucuronyl-(a-1,4)-D-xyluronamide (0.127 mmol, 79 mg) and H 2 SO 4 /SiO 2 22% wt (0.305 mmol, 136 mg) are added in a zirconia bowl containing 80 zirconia balls with a diameter of 5 mm. MeOH (0.15 ml) is added. The medium is ground in a planetary ball mill (P7P)L at 500 rpm for 8 cycles of 5 min with a pause of 2 min, in reverse mode. The methyl ester obtained is directly used in the following reaction under the same grinding conditions.
- P7P planetary ball mill
- the Mal16diBu-perS derivative is obtained according to the same procedure described for obtaining Mal16perS.
- the compound Mal16diBu (35 mg, 0.051 mmol) and 16 equivalents of SO 3 /97% active pyridine complex are introduced into a 20 mL zirconia bowl containing 80 zirconia balls with a diameter of 5 mm, then into the Fritsch P7PL planetary mill.
- the mixture is ground at 400 rpm for 48 cycles of 5 min.
- 16 equivalents of NaHCO 3 69 mg, 0.81 mmol
- the reaction crude is then dissolved in milliQ water and dialyzed using a membrane with a cut-off threshold of 1000kD (3x 500mL).
- Mal16diBu-perS (52 mg) is obtained in the form of A/-hexadecyl-(D-glucuronyl-( ⁇ -1,4)-D-xyluronamide) dibutylamide tri, tetra, penta sulfate mixtures.
- Tau protein phosphorylation is the most common post-translational modification to regulate Tau activity and functions.
- the longest Tau isoform (4R2N, 441 amino acids) containing 85 potential phosphorylation sites was used.
- the in vitro phosphorylation of the Tau protein is carried out on the one hand by induction (FIG. 5) and on the other hand according to a process of competition between the molecules of LG2A and heparin, conventionally used to induce in vitro the abnormal phosphorylation of Tau (figures 3, 4, 6, 7, 8, 9 and 10).
- GSK3[3, a kinase centrally involved in this process in the brains of subjects with Alzheimer's disease (AD) was used.
- the analysis of Tau phosphorylation by GSK3b on sites characteristic of AD is possible by the Western Blot technique using specific antibodies that recognize abnormally phosphorylated sites in the brain or cerebrospinal fluid of AD subjects such as AT270 antibody which recognizes threonine 181 (Thr181), the PHF1 antibody which recognizes serines 396 and 404 (Ser396/Ser404), and the AT8 antibody which recognizes the Ser199/Ser202/Thr205 site.
- composition of the reaction media is as follows:
- the Tau protein (40 pg/ml) (Millipore) is phosphorylated in the presence of ATP (Sigma-Aldrich) at 48 pM, protease inhibitors (Sigma-Aldrich, 1/100), by the enzyme GSK3[3 to 4 ng/ml (Promega), in buffer (40 mM Tris [pH 7.5], 20 mM MgCl 2 , 0.1 mg/ml BSA and 0.1 mM DTT).
- the LG2A molecules are added at 12 pg/ml and their effects compared with that observed by adding the same concentration of heparin.
- the Tau protein (40 pg/ml) is phosphorylated by the GSK3[3 enzyme at 4 ng/ml (Promega) in the presence of ATP (Sigma-Aldrich) at 48 pM, protease inhibitors (Sigma -Aldrich, 1/100), in the buffer cited above.
- the capacity of the molecules of LG2A (60 pg/ml) to enter into competition with heparin (12 pg/ml; Sigma-Aldrich) is evaluated. So if the signal in presence of the molecules is less than that obtained with heparin alone, the molecules are then defined as "protective" of the abnormal phosphorylation of Tau.
- the Tau protein is incubated at 37° C. with stirring in the presence of the various elements presented above.
- the monitoring of the reaction kinetics is carried out by taking 8 pl of the samples at 1.5 h, 3 h and 6 h of incubation.
- Loading buffer (Euromedex) and [3-mercaptoethanol (Sigma-Aldrich) are added to each sample. The samples are then stored at -20°C until analysis by Western Blot.
- the samples After denaturation of the samples by heating at 95°C for 5 minutes, the samples are deposited in parallel with the molecular weight marker (Precision Plus ProteinTM Dual Color Standards; BIO-RAD) on a 10% acrylamide gel placed in a tank electrophoresis containing migration buffer (0.25M Tris; 1.6 M Glycine; 20% SDS; pH of 8.6).
- the molecular weight marker Precision Plus ProteinTM Dual Color Standards; BIO-RAD
- the "native Tau” protein i.e. the non-phosphorylated Tau protein.
- Tau + heparin the Tau protein phosphorylated in the presence of heparin
- the migration takes place at a constant 80 V until the proteins arrive in the separation gel, visualized by the migration front of the bromophenol blue contained in the loading buffer, then at a constant 120 V until the arrival from the migration front to the other end of the gel.
- PVDF polyvinylidene fluoride
- the transfer is operated at 25 V for 10 minutes.
- a saturation step is performed in PBS with 3% skimmed milk powder (Merck Millipore) and 0.1% Tween 20 (VWR) for 1 h with stirring at room temperature. Then the membrane is incubated overnight with stirring at +4°C in a solution of PBS, 0.1% Tween, 1% milk containing the primary antibody specific for the Tau phosphorylation sites (AT270, ThermoScientific or S199 -202, Millipore).
- the compound having the shortest lipid chain length it is preferable to choose the compound having the shortest lipid chain length.
- the melibionamide derivatives comprising a hydrocarbon chain with 14, 16 or 18 carbons respectively “Mel14monoS”, “Mel16monoS and “Mel18monoS) do not compete with heparin for the abnormal phosphorylation of Tau ( Figure 6).
- Melibionamide derivatives comprising a hydrocarbon chain with 14, 16 or 18 carbons respectively “Mel14monoS”, “Mel16monoS and “Mel18monoS) do not compete with heparin for the abnormal phosphorylation of Tau ( Figure 6).
- a single anionic charge or the conformation of the disaccharide is not favorable to enter into competition with heparin and prevent the abnormal phosphorylation of Tau.
- Maltobionamide-like oxidized compounds comprising a 16- or 18-carbon hydrocarbon chain have been synthesized in order to estimate the necessity of the sulfation of the saccharide part of the compounds for their anti-P-Tau activity. It has been observed that oxidized compounds comprising a 16-carbon hydrocarbon chain (“Mal16diOx”) are less effective than disulfated maltobionamide compounds with the same chain length (Mal16diS) in preventing Tau phosphorylation (Figure 7).
- the oxidized compound comprising an 18-carbon hydrocarbon chain (“Mal18diOx”) does not compete with heparin, unlike its disulfated analogue comprising an 18-carbon hydrocarbon chain (“Mal18diS”).
- sulfation of the disaccharide is essential to compete with heparin (prototype of hypersulfated HS present in Alzheimer's disease) and prevent abnormal phosphorylation of Tau.
- derivatives of maltobionamides comprising a hydrocarbon chain with 16 or 18 monosulfated carbons respectively "mal16monoS” and “mal18monoS” or tri-sulfated respectively “mal16triS” and “mal18triS” were synthesized.
- the compounds “Mal16monoS”, “Mal16triS”, “mal18monoS” and “mal18triS” showed (i) a slight loss of the protective capacity of Tau against its heparin-induced phosphorylation when maltobionamide loses a sulfalte (“Mal16monoS and “Mali 8 monoS”) and (ii) a maintenance of this capacity to protect Tau when the compound gains a sulfate (“Mal16triS” and “Mal18triS” (FIG. 8).
- the aggregation test is carried out with the Tau protein (4R2N isoform, 441 amino acids) custom-synthesized by the supplier Tebu-bio (manufacture on 04/17/19; initial Conc: 2.47 mg/ml) in a 96-well black plate with a final volume of 100 ⁇ l and under different conditions: • Tau protein (0.71 mg/ml) alone in buffer (40 mM Tris [pH 7.45], 200 mM NaCl, 2 mM EDTA and 1 mM DTT).
- ThT Sigma-Aldrich
- 100 ⁇ l of ThT 100 ⁇ l of ThT (Sigma-Aldrich) at 50 ⁇ M are immediately added to each of the wells, then the plate is incubated at 37° C. with stirring.
- Monitoring the formation of Tau protein aggregates is possible by monitoring the incorporation of Thioflavin leading to its fluorescence emission and is carried out by reading at 0, 24, 40, 48 and 71 h at wavelengths, ZExc 450 nm / ⁇ Em 510 nm, thanks to the Infinite M1000 spectro-fluorimeter (Tecan).
- the cytotoxicity tests were carried out on the molecules which showed the best potential in the in vitro Tau phosphorylation tests: the 16-carbon and 18-carbon disulfated maltobionamides.
- an MTT test (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) is carried out ( Figures 11 and 12) upstream of the in cellulo phosphorylation tests.
- SH-SY5Y (ATCC-CRL-2266) are grown in Dulbecco's Modified Eagle Complete Medium (DMEM-GlutaMAXTM, Life Technologies) with 10% Fetal Bovine Serum (FCS) and 1% penicillin/streptomycin in an incubator at 37°C with 5% CO 2 .
- DMEM-GlutaMAXTM Dulbecco's Modified Eagle Complete Medium
- FCS Fetal Bovine Serum
- the SH-SY5Y cells are cultured in a 6-well plate at a cell density of 200,000 cells/well and are differentiated using retinoic acid (10 pM, Sigma Aldrich) for 5 days. On the 6th day, the cells are placed in the presence of LG2A molecules at different concentrations (0.1, 1, 10 or 100 pg/ml), in a final volume of 2 ml. After 24 hours, MTT (5 ⁇ g/ml; Sigma-Aldrich) is added to the cell medium for 2 hours at 37°C. The medium is then removed and 200 ⁇ l of pure DiMethylSulfOxide (DMSO, Sigma-Aldrich) is added to each well. The entire content of each well is transferred into a 96-well plate and the absorbance is measured at 562 nm using the Infinite M1000 spectro-fluorimeter (Tecan).
- DMSO DiMethylSulfOxide
- the 16-carbon disulfated maltobionamides are not cytotoxic for SH-SY5Y from the lowest dose of 0.1 pg/ml to the highest dose of 100 pg/ml (FIG. 11).
- the compounds tested have not been shown to induce an additional inflammatory state, via the interleukin 6 assay, of HMC3 cells after stimulation with lipopolysaccharide (LPS) (50 ng/ml) when the compounds are added at doses of 0.1, 1 or 10 pg/ml compared to the same cells receiving only LPS (data not shown).
- LPS lipopolysaccharide
- the SH-SY5Y cells are seeded in 6-well plates and differentiated using retinoic acid (10 ⁇ M, Sigma Aldrich) for 5 days.
- the cells are placed in the presence of Mal16diS and Mal18diS molecules at different concentrations (1, 10 or 100 pg/ml), in a final volume of 2 ml in parallel with a well not receiving any molecules.
- the molecules are removed and the stress inducer (H 2 O 2 , Sigma Aldrich) is added to the cell medium for 30 minutes.
- the cells are then rinsed with 1 ⁇ PBS then lysed and recovered in RIPA buffer (ThermoFischer).
- the protein extracts of the cells (10 pg) are then analyzed by Western Blot according to the same procedure described above.
- the Tau phosphorylation site studied here is the S262 site (Thermo Fisher), normalized on the expression of the GAPDH protein (Sigma Aldrich).
- the quantification of the bands is carried out using the Odyssey software of the LI-COR device, making it possible to calculate the p-Tau/GAPDH ratio for each of the conditions.
- the ratio obtained for each concentration of molecule is then expressed as a percentage of the ratio obtained for the control cells, that is to say cells not treated with the molecules. Thus a value of less than 100% corresponds to a protection provided by the molecules in this cellular model of induction of Tau phosphorylation.
- mal16diS 16-carbon disulfated maltobionamides tested
- mal18diS 18-carbon disulfated maltobionamide
- cell16diS 16-carbon disulfated cellobionamide
- cell16diS 16-carbon disulfated cellobionamide
- lac16diS 16-carbon disulfated lactobionamide
- cortical cells of rTg4510 mice mutated for the human tau protein (P301 L) were used as a model of primary cells expressing tauopathy without induction by an effector unlike the previous cell model (Santa Cruz et al., Science, 2005) .
- the cortical cells are extracted from mouse embryos expressing the P301 L mutation at stage E16 and placed in culture in a 6-well plate. On the 14th (moderate Tau phosphorylation) or 18th (severe Tau phosphorylation) day, the cells extracted from the same embryo are placed in the presence of the Mal16diS molecule at different concentrations (0.1 or 1 pg/ml), in a final volume of 2 ml in parallel with a well of cells from the same embryo not receiving molecules for 24 hours.
- the cells are rinsed with 1 ⁇ PBS then lysed and recovered in RIPA buffer (ThermoFischer).
- the protein extracts of the cells (10 pg) are then analyzed by Western Blot according to the same procedure described above.
- the Tau phosphorylation site investigated here is the S262 site (Thermo Fisher), normalized to total Tau protein expression (K9JA, Dako).
- the quantification of the bands is carried out using the Odyssey software of the LI-COR device, making it possible to calculate the p-Tau/total Tau ratio for each of the conditions.
- the ratio obtained for each concentration of molecule is then expressed as a percentage of the ratio obtained for the cells not treated with the molecules. Thus a value less than 100% corresponds to a protection provided by the molecules in this cellular model of expression of Tau phosphorylation.
- mal16diS 16-carbon disulfated maltobionamide tested
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024531728A JP2024543187A (ja) | 2021-11-29 | 2022-11-29 | タウタンパク質の異常リン酸化及び凝集の阻害物質 |
| CN202280089714.7A CN118922429A (zh) | 2021-11-29 | 2022-11-29 | 异常磷酸化和tau蛋白聚集的抑制剂 |
| US18/714,018 US20250034194A1 (en) | 2021-11-29 | 2022-11-29 | Inhibitors of abnormal phosphorylation and tau protein aggregation |
| EP22823041.3A EP4441064A1 (fr) | 2021-11-29 | 2022-11-29 | Inhibiteurs de la phosphorylation anormale et de l'agrégation de la protéine tau |
| CA3240163A CA3240163A1 (fr) | 2021-11-29 | 2022-11-29 | Inhibiteurs de la phosphorylation anormale et de l'agregation de la proteine tau |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21306658.2 | 2021-11-29 | ||
| EP21306658 | 2021-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023094699A1 true WO2023094699A1 (fr) | 2023-06-01 |
Family
ID=78851140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2022/083709 Ceased WO2023094699A1 (fr) | 2021-11-29 | 2022-11-29 | Inhibiteurs de la phosphorylation anormale et de l'agrégation de la protéine tau |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250034194A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4441064A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024543187A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118922429A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3240163A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023094699A1 (cg-RX-API-DMAC10.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024258815A1 (en) * | 2023-06-12 | 2024-12-19 | The Procter & Gamble Company | Gluconamide sulfate surfactants |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686603A (en) * | 1995-05-04 | 1997-11-11 | Lever Brothers Company, Division Of Conopco, Inc. | Sulfated polyhydroxy compounds as anionic surfactants and a process for their manufacture |
| WO2007115372A1 (en) * | 2006-04-10 | 2007-10-18 | Monash University | A method of modulating beta-amyloid peptide production |
-
2022
- 2022-11-29 CA CA3240163A patent/CA3240163A1/fr active Pending
- 2022-11-29 JP JP2024531728A patent/JP2024543187A/ja active Pending
- 2022-11-29 WO PCT/EP2022/083709 patent/WO2023094699A1/fr not_active Ceased
- 2022-11-29 CN CN202280089714.7A patent/CN118922429A/zh active Pending
- 2022-11-29 EP EP22823041.3A patent/EP4441064A1/fr active Pending
- 2022-11-29 US US18/714,018 patent/US20250034194A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686603A (en) * | 1995-05-04 | 1997-11-11 | Lever Brothers Company, Division Of Conopco, Inc. | Sulfated polyhydroxy compounds as anionic surfactants and a process for their manufacture |
| WO2007115372A1 (en) * | 2006-04-10 | 2007-10-18 | Monash University | A method of modulating beta-amyloid peptide production |
Non-Patent Citations (14)
| Title |
|---|
| ACS SUSTAINABLE CHEM. ENG., vol. 4, 2016, pages 2432 - 2438 |
| ACS SUSTAINABLE CHEMISTRY & ENGINEERING, vol. 4, no. 4, 2016, pages 2432 - 2438 |
| COGGINS, A. J. ET AL., NATURE CHEMISTRY, vol. 9, no. 4, 2017, pages 310 - 317 |
| GOEDERT M ET AL., NATURE, vol. 383, no. 6600, 10 October 1996 (1996-10-10), pages 550 - 3 |
| HOLMES BB ET AL., PROC NATL ACAD SCI USA., vol. 110, 13 August 2013 (2013-08-13) |
| LEE Y ET AL., CHEM COMMUN, 2014, pages 50 |
| LU, H ET AL., MOLECULES, vol. 21, no. 10, 2016 |
| MAÏZA A ET AL., FEBS LETT, vol. 592, no. 23, December 2018 (2018-12-01), pages 3806 - 3818 |
| OMRI M. ET AL., ACS CATALYSIS, 2018 |
| SANTA CRUZ ET AL., SCIENCE, 2005 |
| SCHROEDER SK ET AL., NEUROIMMUNE PHARMACOL, vol. 11, no. 1, 2016, pages 9 - 25 |
| SEPULVEDA-DIAZ JE ET AL., BRAIN, vol. 138, May 2015 (2015-05-01), pages 1339 - 54 |
| TETRAHEDRON, vol. 66, no. 16, 17 April 2010 (2010-04-17), pages 2907 - 2918 |
| ZHAO J ET AL., BIOPHYS J., vol. 112, no. 5, 14 March 2017 (2017-03-14), pages 921 - 932 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024258815A1 (en) * | 2023-06-12 | 2024-12-19 | The Procter & Gamble Company | Gluconamide sulfate surfactants |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118922429A (zh) | 2024-11-08 |
| US20250034194A1 (en) | 2025-01-30 |
| CA3240163A1 (fr) | 2023-06-01 |
| JP2024543187A (ja) | 2024-11-19 |
| EP4441064A1 (fr) | 2024-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3116511B1 (en) | Compositions of selenoorganic compounds and methods of use thereof | |
| CN113727966A (zh) | 泛硫醇衍生物及其用途 | |
| CN106456699A (zh) | 作为抗老化剂抑制抗凋亡的Bcl‑2蛋白的组合物和方法 | |
| EP1231916A2 (fr) | Utilisation de derives d'indirubine pour la fabrication de medicaments | |
| Li et al. | Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH2) derivatives as potent agents to ameliorate inflammation and increase mitochondrial ATP synthesis | |
| EP4441064A1 (fr) | Inhibiteurs de la phosphorylation anormale et de l'agrégation de la protéine tau | |
| EP3785709A1 (fr) | Composition pharmaceutique destinée à inhiber l'infectiosité du vih, à traiter le syndrome d'immunodéficience acquise (sida) et ses complications | |
| WO2005039589A2 (fr) | Modulateurs des canaux cftr | |
| WO2004032708A2 (en) | Vasoregulating compounds and methods of their use | |
| JP2008529998A (ja) | トポイソメラーゼII触媒インヒビターとしての6−エーテル/チオエーテル−プリンおよび療法(therapy)におけるその用途 | |
| CA2896435A1 (en) | Use of adelmidrol in the treatment of epithelial dysfunctions | |
| JP2025505975A (ja) | ニコチネート及びニコチンアミドリボシドベースの化合物及びその誘導体 | |
| EP4291217B1 (fr) | Composition thérapeutique à base de feuilles de neurolaena inhibitrice de la dhodh pour le traitement d'infections par virus à arn | |
| US20150191446A1 (en) | Seleno-compounds and therapeutic uses thereof | |
| Pan et al. | Mobilization of intracellular calcium by peroxynitrite in arteriolar smooth muscle cells from rats | |
| CA3130046C (fr) | Inhibiteur d'acyl-thioesterases pour le traitement et/ou la prevention de la maladie de huntington | |
| EP4225295B1 (fr) | Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique | |
| US20240398889A1 (en) | Nutraceutical composition and method for the protection of human arterial endothelial cells from endothelial cell dysfunction | |
| RU2744453C2 (ru) | Таргетная неинвазивная трансплантация в мозг функционально активных митохондрий для лечения нейродегенеративных заболеваний | |
| EP3144001A1 (en) | Compositions of selenoorganic compounds and methods of use thereof | |
| FR3119540A1 (fr) | Composition thérapeutique inhibitrice de la DHODH | |
| EP3752138B1 (fr) | Composés et compositions pour le traitement de maladies neurodégénératives et inflammatoires | |
| EP4408410A1 (fr) | Inhibiteurs de l'interaction entre les protéines kinases rock et pdk1 | |
| WO2024112683A1 (en) | Nutraceutical compositions and methods for the protection of human arterial endothelial cells from endothelial cell dysfunction | |
| WO2020170208A1 (fr) | Inhibiteur d'acyl-thioestérases pour le traitement et/ou la prévention de la maladie de huntington |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22823041 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 3240163 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2024531728 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 18714018 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2022823041 Country of ref document: EP Effective date: 20240701 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202280089714.7 Country of ref document: CN |